The purpose of this Funding Opportunity Announcement (FOA) is to develop clinical-grade prototype devices intended for use as safe, effective, and non-addictive diagnostics and treatments for pain or opioid use disorder (OUD). The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain or OUD, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain or OUD. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use.
Deadlines:
- Letter of Intent Due Date(s): 30 days prior to receipt date
- Application Due Date(s): Nov. 14, 2022; June 19, 2023; Feb 20, 2024; Oct 15, 2024;
RFA-EB-22-002 Expiration Date New Date April 16, 2025 per NOT-EB-25-001 (Prior Date June 18, 2025). Any due dates beyond the new expiration date are no longer available.
Application budgets are not limited, but need to reflect the actual needs of the proposed project.
Budgets should rarely exceed $750,000 direct cost per year.
Applications may request up to three years of support. However, the scope of the proposed project should determine the project period.